GHENT, BELGIUM--(Marketwire - January 14, 2009) -
-- Pulmonary delivery of anti-viral Nanobodies® gives extended
protection against viral infection in vivo
-- In vivo proof of concept for its novel proprietary half-life extension technology
Ablynx [Euronext Brussels: ABLX],
a pioneer in the discovery and development of Nanobodies®, a novel
class of antibody-derived therapeutic proteins, announced today two
significant advances achieved with its Nanobody® platform. In the
first, it has shown that anti-viral Nanobodies® give extended
protection against viral infection in vivo when administered via an
intrapulmonary route. In the second, Ablynx has demonstrated in vivo
proof of concept for a proprietary novel half-life(*) extension
technology which allows the half-life of its Nanobody®-based
therapeutics to be tailored depending on the disease indication.
Pulmonary delivery of Nanobodies®
Ablynx has demonstrated that anti-viral Nanobodies® protect against signs of viral infection and presence of active virus when delivered via an intrapulmonary route. Following a single administration of the Nanobodies® via the lungs, neutralization of virus was observed for at least 72 hours.
Additionally, Ablynx has shown that Nanobodies® are suitable for systemic delivery(**) via the lungs. Their extended bioavailability is increased by a factor of five to ten times compared with intravenous administration.
Ablynx is also investigating other alternative delivery technologies for its Nanobodies® including oral to systemic delivery and needleless administration.
Novel proprietary half-life extension technology
Ablynx has access to several different methods to tailor the half-life of its Nanobodies® depending on the desired characteristics of the therapeutic drug candidate and the indication. The Company announced today that they have discovered and developed a novel proprietary half-life extension technology and demonstrated in vivo results which show considerable potential to significantly increase the half-life for its Nanobodies® in humans.
Please see link below for the complete version of this press release
For more information, please contact: College Hill Life Sciences - for UK/International media enquiries: Sue Charles, Justine Lamond, John McIntyre t: +44 (0)20 7866 7857 f: +44 (0)20 7866 7900 e: ablynx@collegehill.com Ablynx: Dr. Edwin Moses Chairman and CEO t: +32 (0)9 262 00 07 m: +44 (0)7771 954 193 / +32 (0)473 39 50 68 e: edwin.moses@ablynx.com Eva-Lotta Allan Chief Business Officer t: +32 (0)9 262 00 75 m: +32 (0)475 78 36 21 / +44 (0)7990 570 900 e: eva-lotta.allan@ablynx.com
Complete version of the press release in English: (http://hugin.info/137912/R/1282211/286864.pdf)
This announcement was originally distributed by Hugin. The issuer is
solely responsible for the content of this announcement.
Copyright © Hugin AS 2009. All rights reserved.
